comparemela.com
Home
Live Updates
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B : comparemela.com
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration...
Related Keywords
China ,
Shaoxing ,
Zhejiang ,
United States ,
Hong Kong ,
Hangzhou ,
American ,
Jinzij Wu ,
,
Hong Kong Stock Exchange ,
Human Services ,
Us Department Of Health ,
World Health Organization ,
Drug Administration ,
Ascletis Pharma Inc ,
Ascletis Pharma ,
Investigational New Drug ,
Chronic Hepatitisb Virus Infection ,
Late Breaking Session ,
American Association ,
Liver Diseases ,
Liver Meeting ,
Suzhou Alphamab ,
Hepatitisb Virus ,
Primary Biliary Cholangitis ,
comparemela.com © 2020. All Rights Reserved.